Glutaminase (GLS) inhibitors, such as CB-839, have shown significant promise in preclinical studies by blocking the conversion of glutamine to glutamate, thereby depriving tumor cells of essential substrates for biosynthesis and energy production. The gene discussed is GLS; the disease is neoplasm.